NCT06884748View on ClinicalTrials.gov

Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2028

Conditions
Clostridioides Difficile Infection
Interventions
DRUG

Ursodiol 500 MG

Standard of care treatment (Flagyl, Vancomycin or Fidaxomicin) + UDCA 500 mg TID for 8 weeks. UDCA to be started while patient is on antibiotics for C. difficile and continue for 8 weeks total.

Trial Locations (1)

53226

Daniel Stein, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER

NCT06884748 - Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy | Biotech Hunter | Biotech Hunter